Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
The risk of recurrence from stage II colon cancer and benefit from adjuvant chemotherapy is influenced significantly by the molecular marker termed microsatellite instability and/or mismatch repair (MMR) gene product expression.1 Study results and the National Comprehensive Cancer Network Colon Cancer Guideline panel suggest that adjuvant chemotherapy (fluoropyrimidine [5-FU] +/- oxaliplatin) be considered for patients with stage II colon adenocarcinoma harboring one or more "high-risk" features.2 However, for patients with deficient-MMR (dMMR) stage II colon cancer, evidence suggests there may be a detrimental effect with adjuvant 5-FU alone.3 Finally, the addition of oxaliplatin to 5-FU does not appear to benefit older patients with stage II colon cancer.4,5 For the patient described, the challenge involved how to advise an older patient with a dMMR stage II colon cancer and a high-risk feature. The identified lymphovascular invasion in the tumor implies that adjuvant chemotherapy with either 5-FU or capecitabine +/- oxaliplatin would be reasonable considerations. However, the dMMR status of the tumor suggests that 5-FU alone would be contraindicated, and her age suggests that a lack of benefit would be expected from oxaliplatin.